<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Radiat Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Med Radiat Sci</journal-id><journal-id journal-id-type="publisher-id">jmrs</journal-id><journal-title-group><journal-title>Journal of Medical Radiation Sciences</journal-title></journal-title-group><issn pub-type="ppub">2051-3895</issn><issn pub-type="epub">2051-3909</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26229674</article-id><article-id pub-id-type="pmc">4462981</article-id><article-id pub-id-type="doi">10.1002/jmrs.99</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Elizabeth</given-names></name><degrees>MHealthSc (MRS)</degrees><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Cray</surname><given-names>Alison</given-names></name><degrees>Grad Dip AppSc (RT)</degrees><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Haworth</surname><given-names>Annette</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chander</surname><given-names>Sarat</given-names></name><degrees>MBBS, FRANCZR</degrees><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Robert</given-names></name><degrees>HScD</degrees><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Subramanian</surname><given-names>Brindha</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ng</surname><given-names>Michael</given-names></name><degrees>MBBS (Hons) FRANZCR</degrees><xref ref-type="aff" rid="au5">5</xref></contrib><aff id="au1"><label>1</label><institution>Princess Alexandra Hospital</institution><addr-line>Brisbane, Queensland, Australia</addr-line></aff><aff id="au2"><label>2</label><institution>Peter MacCallum Cancer Cancer Centre</institution><addr-line>Box Hill, Victoria, Australia</addr-line></aff><aff id="au3"><label>3</label><institution>University of Melbourne</institution><addr-line>Melbourne, Victoria, Australia</addr-line></aff><aff id="au4"><label>4</label><institution>Medica Oncology</institution><addr-line>Hurstville, New South Wales, Australia</addr-line></aff><aff id="au5"><label>5</label><institution>Radiation Oncology Victoria</institution><addr-line>Melbourne, Victoria, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Elizabeth Brown, Radiation Oncology Department, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Queensland 4102, Australia. Tel: +61 7 31766569; Fax: +61 7 31766127; E-mail: <email>elizabeth@mebrown.net</email></corresp><fn><p><bold>Funding Information</bold> The Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Project was funded by the Australian Government.</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2015</year></pub-date><volume>62</volume><issue>2</issue><fpage>99</fpage><lpage>107</lpage><history><date date-type="received"><day>30</day><month>10</month><year>2014</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 The Authors. <italic>Journal of Medical Radiation Sciences</italic> published by Wiley Publishing Asia Pty Ltd on behalf of Australian Institute of Radiography and New Zealand Institute of Medical Radiation Technology.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Intensity modulated radiotherapy (IMRT) is ideal for anal canal cancer (ACC), delivering high doses to irregular tumour volumes whilst minimising dose to surrounding normal tissues. Establishing achievable dose objectives is a challenge. The purpose of this paper was to utilise data collected in the Assessment of New Radiation Oncology Treatments and Technologies (ANROTAT) project to evaluate the feasibility of ACC IMRT dose planning objectives employed in the Australian situation.</p></sec><sec><title>Methods</title><p>Ten Australian centres were randomly allocated three data sets from 15 non-identifiable computed tomography data sets representing a range of disease stages and gender. Each data set was planned by two different centres, producing 30 plans. All tumour and organ at risk (OAR) contours, prescription and dose constraint details were provided. Dose&#x02013;volume histograms (DVHs) for each plan were analysed to evaluate the feasibility of dose planning objectives provided.</p></sec><sec><title>Results</title><p>All dose planning objectives for the bone marrow (BM) and femoral heads were achieved. Median planned doses exceeded one or more objectives for bowel, external genitalia and bladder. This reached statistical significance for bowel V30 (<italic>P</italic>&#x000a0;=&#x000a0;0.04), V45 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), V50 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), external genitalia V20 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and bladder V35 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), V40 (<italic>P</italic>&#x000a0;=&#x000a0;0.01). Gender was found to be the only significant factor in the likelihood of achieving the bowel V50 (<italic>P</italic>&#x000a0;=&#x000a0;0.03) and BM V30 constraints (<italic>P</italic>&#x000a0;=&#x000a0;0.04).</p></sec><sec><title>Conclusion</title><p>The dose planning objectives used in the ANROTAT project provide a good starting point for ACC IMRT planning. To facilitate clinical implementation, it is important to prioritise OAR objectives and recognise factors that affect the achievability of these objectives.</p></sec></abstract><kwd-group><kwd>Anal canal</kwd><kwd>anus neoplasms</kwd><kwd>intensity</kwd><kwd>modulated</kwd><kwd>radiation oncology</kwd><kwd>radiotherapy</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The optimal treatment technique for anal canal cancer (ACC) has traditionally presented a challenge to the radiotherapy community. The highly irregular target volumes associated with ACC combined with the presence of numerous organs at risk (OAR) within close proximity means that achieving the ideal therapeutic ratio can be problematic.<xref rid="b1" ref-type="bibr">1</xref> Traditionally used radiotherapy techniques, such as three-dimensional conformal radiation therapy, can result in severe acute toxicity potentially impacting treatment continuity. These acute and late toxicities included moist skin desquamation, diarrhoea, dysuria, marrow suppression, perineal skin atrophy and fibrosis and femoral neck fractures.<xref rid="b1" ref-type="bibr">1</xref>&#x02013;<xref rid="b6" ref-type="bibr">6</xref> The impact of these acute toxicities is that some patients may require a treatment break to recover from their toxicities or may not actually complete treatment, potentially leading to a compromise in tumour control.<xref rid="b7" ref-type="bibr">7</xref>&#x02013;<xref rid="b9" ref-type="bibr">9</xref> It is difficult with traditional techniques to reduce dose to many OAR and therefore minimise toxicity. Intensity modulated radiotherapy (IMRT) allows highly conformal treatment plans to be produced and is well suited for use in ACC to minimise OAR dose and toxicity whilst still delivering the prescribed dose to the tumour thus enabling the patient to complete the intended treatment without interruption.<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref></p><p>The use of IMRT in ACC is still relatively new in Australia. A survey of 16 radiotherapy departments around Australia in 2010 showed limited use and experience of IMRT in ACC.<xref rid="b12" ref-type="bibr">12</xref> One of the major challenges associated with introducing IMRT planning for ACC is establishing achievable dose planning objectives to facilitate adequate dermatologic, gastrointestinal, genitourinary and bone marrow (BM) sparing whilst maintaining prescribed high doses to the tumour. The aims of the study were to (1) evaluate the ability of plans created during a technology assessment project to meet a defined set of planning objectives and (2) identify factors that may impact on the ability to meet these planning objectives. This information could assist departments inexperienced with IMRT for ACC in selecting achievable dose planning objectives for use.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data collection</title><p>The data utilised in this investigation were collected from part of the Assessment of New Radiation Oncology Treatments and Technologies (ANROTAT) project. This project was undertaken by the Trans Tasman Radiation Oncology Group (TROG) in response to a commission by the Australian Government Department of Health and Ageing to develop and pilot an evaluation framework of new technologies with a view to providing improved funding for IMRT if evidence compiled by the project was compelling.<xref rid="b13" ref-type="bibr">13</xref> The purpose, objectives and specific details of the project are described in the ANROTAT protocol.<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b13" ref-type="bibr">13</xref> Data collection occurred between June 2011 and April 2012. The ACC section of the ANROTAT project consisted of five component studies including credentialing, dosimetry and prospective toxicity and quality of life assessment. The data collected in the IMRT dosimetry component of the project have been utilised in this investigation.</p></sec><sec><title>Data set details</title><p>Fifteen non-identifiable retrospective computed tomography (CT) data sets were selected. Eligibility criteria included histological confirmation of squamous cell carcinoma, intention to electively irradiate all pelvic nodal groups up to L5-S1 interspace (including mesorectal, presacral, internal iliac, external iliac, ischiorectal fossa, obturator and inguinal groups) and planned for radical chemoradiotherapy. Patient CT data sets were excluded if there was evidence of metastatic disease, if they had prior pelvic radiotherapy or surgery (e.g. vaginal hysterectomy) or had a hip prosthesis. The selection comprised a mix of different stages for both male and female patients, all positioned supine, who met the eligibility criteria (Table<xref ref-type="table" rid="tbl1">1</xref>). Stage T1N0 was excluded, as some centres do not routinely electively irradiate the inguinal nodes in this setting. Ethics approval was obtained for use of the retrospective data sets for all participating centres.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Data set characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">Number (<italic>n&#x000a0;</italic>=&#x000a0;15)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Median age (range)</td><td align="left" rowspan="1" colspan="1">58 (42&#x02013;83)</td></tr><tr><td align="left" colspan="2" rowspan="1"><italic>T</italic> stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;4</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" colspan="2" rowspan="1"><italic>N</italic> stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" colspan="2" rowspan="1">Stage</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2 (T2-3N0)</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3A (T1-3N1, T4N0)</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3B (T4N1, AnyTN2-3)</td><td align="left" rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><p>Ten radiotherapy centres across Australia participated in the project. This included public and private, metropolitan and rural and large and small departments. Each of the participating centres were allocated three of the 15 data sets, and prepared an IMRT plan for each data set. Each data set was planned by two centres. The plans and associated documentation were then submitted for review by the project team. The review team consisted of two radiation oncologists and three radiation therapists.</p></sec><sec><title>Contouring</title><p>As the purpose of this investigation was to evaluate dose distribution and not to assess variations in contouring, all target volumes and OAR structure sets were included with each CT data set. Target volume contours were marked and reviewed by two radiation oncologists and were delineated using the guidelines proposed by the Australasian Gastrointestinal Trials Group (AGITG).<xref rid="b14" ref-type="bibr">14</xref> Target volumes provided were planning target volume (PTV) 45&#x000a0;Gy (elective volume), PTV54&#x000a0;Gy-p (primary volumes with &#x02018;p&#x02019; representing primary), PTV54&#x000a0;Gy&#x02013;n1, n2 and n3 (&#x02018;n&#x02019; represents node with the &#x02018;1, 2, 3&#x02019; representing the number of involved nodes). A 1&#x000a0;cm clinical target volume (CTV) to PTV margin was employed for all data sets. If the PTV contour extended outside the skin, it was cropped to the skin surface. For planning purposes, objective PTV volumes cropped 5&#x000a0;mm from the skin surface were created by the centre for plan optimisation. OAR contours provided included BM, bowel, left and right femoral head and necks, external genitalia and bladder.<xref rid="b12" ref-type="bibr">12</xref> The bowel was delineated as a cavity, 15&#x000a0;mm superior to the cranial aspect of the PTV, extending inferiorly to the recto-sigmoid junction based on the study by Devisetty and colleagues.<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b16" ref-type="bibr">16</xref> External genitalia included the perineum with the cranial extent at the upper level of the pubic symphysis.</p></sec><sec><title>Prescription and dose constraints</title><p>All IMRT plans were generated using a simultaneous integrated boost technique according to the ANROTAT protocol.<xref rid="b12" ref-type="bibr">12</xref> The prescription consisted of two dose levels (1) PTV-45&#x000a0;Gy receiving 45&#x000a0;Gy and (2) PTV-54&#x000a0;Gy receiving 54&#x000a0;Gy delivered over 30 fractions. Dose coverage requirements and dose planning objectives for OAR for the ANROTAT protocol are shown in Table<xref ref-type="table" rid="tbl2">2</xref>. The primary objective was to achieve target volume coverage followed by the OAR dose constraints and planning objectives listed in order from most to least important. These constraints were adapted from the Radiation Therapy Oncology Group (RTOG) 05-29 phase 2 study protocol that assessed IMRT in anal cancer with one exception.<xref rid="b17" ref-type="bibr">17</xref> The small bowel constraint was modified to bowel based on data published by Devisetty and colleagues.<xref rid="b16" ref-type="bibr">16</xref> This paper provided dose&#x02013;volume correlation with acute bowel toxicity in ACC patients undergoing chemoradiation, and hence supported the ANROTAT project's health economic analyses. At the commencement of the ANROTAT project, there was no other relevant literature providing OAR dose correlation with acute toxicity in ACC radiotherapy.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>IMRT dose planning objectives/constraints</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Structure</th><th align="left" rowspan="1" colspan="1">Dose constraint</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Target volumes</td><td align="left" rowspan="1" colspan="1">D98&#x000a0;&#x02265;&#x000a0;95%</td></tr><tr><td align="left" rowspan="1" colspan="1">D2&#x000a0;&#x02264;&#x000a0;115%</td></tr><tr><td align="left" rowspan="4" colspan="1">Bowel</td><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x02264;&#x000a0;350&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V35&#x000a0;&#x02264;&#x000a0;150&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V45&#x000a0;&#x02264;&#x000a0;20&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V50&#x000a0;=&#x000a0;0&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="2" colspan="1">Left and right femoral heads</td><td align="left" rowspan="1" colspan="1">V40&#x000a0;&#x02264;&#x000a0;35%</td></tr><tr><td align="left" rowspan="1" colspan="1">V44&#x000a0;&#x02264;&#x000a0;5%</td></tr><tr><td align="left" rowspan="3" colspan="1">Bone marrow</td><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x02264;&#x000a0;50%</td></tr><tr><td align="left" rowspan="1" colspan="1">V40&#x000a0;&#x02264;&#x000a0;35%</td></tr><tr><td align="left" rowspan="1" colspan="1">V50&#x000a0;&#x02264;&#x000a0;5%</td></tr><tr><td align="left" rowspan="3" colspan="1">External genitalia</td><td align="left" rowspan="1" colspan="1">V20&#x000a0;&#x02264;&#x000a0;50%</td></tr><tr><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x02264;&#x000a0;35%</td></tr><tr><td align="left" rowspan="1" colspan="1">V40&#x000a0;&#x02264;&#x000a0;5%</td></tr><tr><td align="left" rowspan="3" colspan="1">Bladder</td><td align="left" rowspan="1" colspan="1">V35&#x000a0;&#x02264;&#x000a0;50%</td></tr><tr><td align="left" rowspan="1" colspan="1">V40&#x000a0;&#x02264;&#x000a0;35%</td></tr><tr><td align="left" rowspan="1" colspan="1">V50&#x000a0;&#x02264;&#x000a0;5%</td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><p>Dose planning objectives are listed in descending order of priority. Dx, dose covering x% of the volume; Vx, volume of organ receiving xGy.</p></fn></table-wrap-foot></table-wrap><p>Centres were directed that effort should be made to achieve the listed dose constraints but were advised that constraints cannot always be achieved, and therefore planning objectives were specified listed in order from highest to lowest priority. Failure to meet some dose constraints would result in minor or major deviations (Table<xref ref-type="table" rid="tbl3">3</xref>). These deviations were set by the group to assist in assessing clinical safety and compliance. The only OAR that major deviation levels were specified for were the bowel and femoral heads as&#x000a0;these were the only two OAR with published dose&#x02013;volume toxicity data in ACC patients for acute bowel toxicity and femoral neck fractures.<xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b18" ref-type="bibr">18</xref> The threshold levels for these structures were based on these studies.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Plan review definitions of major and minor deviations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Structure</th><th align="left" rowspan="1" colspan="1">Acceptable</th><th align="left" rowspan="1" colspan="1">Minor</th><th align="left" rowspan="1" colspan="1">Major</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">PTVs</td><td align="left" rowspan="1" colspan="1">D98&#x000a0;&#x02265;&#x000a0;95%</td><td align="left" rowspan="1" colspan="1">D98&#x000a0;&#x02265;&#x000a0;90% to &#x0003c;95%</td><td align="left" rowspan="1" colspan="1">D98&#x000a0;&#x0003c;&#x000a0;90%</td></tr><tr><td align="left" rowspan="1" colspan="1">D2&#x000a0;&#x02264;&#x000a0;115%</td><td align="left" rowspan="1" colspan="1">D2&#x000a0;&#x0003e;&#x000a0;115%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Small bowel</td><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x02264;&#x000a0;350&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x0003e;&#x000a0;400&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">V30&#x000a0;&#x0003e;&#x000a0;450&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V45&#x000a0;&#x02264;&#x000a0;20&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">V45&#x000a0;&#x0003e;&#x000a0;30&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">V50&#x000a0;&#x0003e;&#x000a0;0&#x000a0;cm<sup>3</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">V50&#x000a0;=&#x000a0;0&#x000a0;cm<sup>3</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Femoral heads</td><td align="left" rowspan="1" colspan="1">V40&#x000a0;&#x02264;&#x000a0;35%</td><td align="left" rowspan="1" colspan="1">V44&#x000a0;&#x0003e;&#x000a0;5% to &#x02264;10%</td><td align="left" rowspan="1" colspan="1">V44&#x000a0;&#x0003e;&#x000a0;10%</td></tr><tr><td align="left" rowspan="1" colspan="1">V44&#x000a0;&#x02264;&#x000a0;5%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tf3-1"><p>PTVs, planning target volumes; Dx, dose covering x% of the volume; Vx, volume of organ receiving xGy.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Dosimetric assessment</title><p>All plans were submitted electronically in DICOM RT or RTOG format for review using the Focal treatment planning system (Elekta AB, Stockholm, Sweden).<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref> Data export included dose&#x02013;volume histograms (DVHs) for all target and OAR volumes; however, the DVHs were recalculated using the Focal treatment planning system to ensure consistency in volume calculation methods.<xref rid="b21" ref-type="bibr">21</xref> The quality assurance team reviewed each plan and recorded the actual calculated dose for the target volumes and OAR for each of the specified dose constraint and planning objective levels.</p></sec><sec><title>Planning technique</title><p>Centres were instructed to follow their departmental procedures with regard to IMRT planning technique; however, a recommendation to use seven to nine beams was made.<xref rid="b12" ref-type="bibr">12</xref> For centres unfamiliar with IMRT planning for ACC, an IMRT planning guide was included as an appendix to the protocol.<xref rid="b12" ref-type="bibr">12</xref></p></sec><sec><title>Statistics</title><p>Data were analysed using the Stata (version 12.1; StataCorp LP, College Station, TX) program. Doses to target volumes and OAR, were recorded for all submitted IMRT plans. Statistical analysis included basic descriptive statistics and the <italic>t</italic>-test or Wilcoxon signed rank test (where data were not normally distributed) to establish what dose objectives were actually achieved for each OAR. The Mann&#x02013;Whitney test was used to compare groups based on gender and <italic>N</italic> stage in the achievability of dose objectives and logistic regression was used to determine factors of significance in the ability to achieve the dose objectives. Factors considered were gender, <italic>T</italic> stage and <italic>N</italic> stage. <italic>N</italic> stage was investigated as a whole, in addition to being divided into two groups: (1) <italic>N</italic>0&#x02013;<italic>N</italic>2 and (2) <italic>N</italic>3 only. <italic>N</italic>3 disease was considered as a separate group as this stage included bilateral inguinal or internal iliac involvement that results in higher doses delivered to the pelvis and surrounding OAR. A <italic>P</italic>-value of 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Planning data</title><p>Data sets were planned using a median of 9 (range 7&#x02013;21 beams) co-planar, step-and-shoot IMRT beams. The large number of beams required in some instances can be attributed to the requirement of a &#x02018;carriage shift&#x02019; in the transfer of the beams from the treatment planning system to the linac (meaning some beams were split into two). Of the 30 plans submitted, an average total monitor units (MU) of 965 with a range of 476&#x02013;1683&#x000a0;MU was recorded for 27 plans. The total MU was not recorded for three plans. The average time purely spent planning (not including review or quality assurance time) was 343.7&#x000a0;min (range 50&#x02013;868&#x000a0;min).</p></sec><sec><title>Target volumes</title><p>A total of 30 IMRT plans were reviewed and target volume coverage was achieved. The mean coverage of 98% of PTV45&#x000a0;Gy, PTV54&#x000a0;Gy-p and PTV54&#x000a0;Gy-n (D98) was at least 95% of the prescribed dose level with mean doses of 44.9, 51.9 and 51.5&#x000a0;Gy respectively.</p></sec><sec><title>OAR volumes</title><p>A comparison of OAR dose planning objectives and the achieved dose/volumes is shown in Table<xref ref-type="table" rid="tbl4">4</xref>. The percentage of plans that failed each OAR dose planning objective, in addition to the percentage of plans that classified as a major deviation for the applicable OAR, is displayed in Table<xref ref-type="table" rid="tbl5">5</xref>. Median planned doses exceeded one or more of the planning objectives for the bowel, external genitalia and bladder with more than 50% of plans failing two out of three planning objectives assessed for these OAR. In contrast, all median planned doses for the BM and femoral head and necks met the defined planning objectives. The median planned volume significantly exceeded the prescribed dose constraint/planning objective by 39.9&#x000a0;cm<sup>3</sup> for bowel V45 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and 1.1&#x000a0;cm<sup>3</sup> for bowel V50 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), 16.3% for external genitalia V20 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), 16.5% for bladder V35 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and 6.2% for bladder V40 (<italic>P</italic>&#x000a0;=&#x000a0;0.01).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Comparison of OAR dose planning objectives/constraints with the mean value from submitted plans. Absolute volumes are indicated in units of cm<sup>3</sup>, remaining values are a percentage of the defined volume</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">OAR</th><th align="left" rowspan="1" colspan="1">Dose level (Gy)</th><th align="left" rowspan="1" colspan="1">Dose planning objective/constraint (%)</th><th align="left" rowspan="1" colspan="1">Median achieved volume (range) (%)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Bowel</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">350&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">217.1&#x000a0;cm<sup>3</sup> (974.7)</td><td align="left" rowspan="1" colspan="1">0.04<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V45</td><td align="left" rowspan="1" colspan="1">20&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">59.9&#x000a0;cm<sup>3</sup> (916.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">0&#x000a0;cm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">1.1&#x000a0;cm<sup>3</sup> (865.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="2" colspan="1">Left femoral head</td><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">17.1 (48.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V44</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.7 (35.4)</td><td align="left" rowspan="1" colspan="1">0.04<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="2" colspan="1">Right femoral head</td><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">14.2 (46.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V44</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.0 (30.2)</td><td align="left" rowspan="1" colspan="1">0.02<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="3" colspan="1">Bone marrow</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">45.8 (40.5)</td><td align="left" rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">22.9 (36.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.01 (8.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="3" colspan="1">External genitalia/perineum</td><td align="left" rowspan="1" colspan="1">V20</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">66.3 (56.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">32.7 (81.0)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4.9 (47.5)</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="3" colspan="1">Bladder</td><td align="left" rowspan="1" colspan="1">V35</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">66.5 (58.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">41.2 (80.0)</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tf4-2">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.0 (29.8)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr></tbody></table><table-wrap-foot><fn id="tf4-1"><p>OAR, organs at risk; Vx, volume of organ receiving xGy.</p></fn><fn id="tf4-2"><label>*</label><p>Denotes statistical significance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p>Percentage of plans that failed each OAR dose planning objective</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">OAR</th><th align="left" rowspan="1" colspan="1">Dose level (Gy)</th><th align="left" rowspan="1" colspan="1">Fail (%) (% major deviation)</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Bowel</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(13.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">V45</td><td align="left" rowspan="1" colspan="1">73.3</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">50</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(50)</td></tr><tr><td align="left" rowspan="2" colspan="1">Left femoral head</td><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">13.8</td></tr><tr><td align="left" rowspan="1" colspan="1">V44</td><td align="left" rowspan="1" colspan="1">24.1</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(10.3)</td></tr><tr><td align="left" rowspan="2" colspan="1">Right femoral head</td><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">6.7</td></tr><tr><td align="left" rowspan="1" colspan="1">V44</td><td align="left" rowspan="1" colspan="1">26.7</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(10)</td></tr><tr><td align="left" rowspan="3" colspan="1">Bone marrow</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">23.3</td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">6.7</td></tr><tr><td align="left" rowspan="3" colspan="1">External genitalia/perineum</td><td align="left" rowspan="1" colspan="1">V20</td><td align="left" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">46.7</td></tr><tr><td align="left" rowspan="3" colspan="1">Bladder</td><td align="left" rowspan="1" colspan="1">V35</td><td align="left" rowspan="1" colspan="1">73.3</td></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">40</td></tr></tbody></table><table-wrap-foot><fn id="tf5-1"><p>OAR, organs at risk; Vx, volume of organ receiving xGy.</p></fn></table-wrap-foot></table-wrap><p>A statistically significant difference was demonstrated between the median volumes achieved for bowel V30 (<italic>P</italic>&#x000a0;=&#x000a0;0.04) and BM V30 (<italic>P</italic>&#x000a0;=&#x000a0;0.03) and BM V40 (<italic>P</italic>&#x000a0;=&#x000a0;0.05) when considering patient gender. Differences were approaching statistical significance for the bowel V45 and V50 objectives. Specifically, the median volume for these OAR in female patient data sets exceeded the male data sets (Table<xref ref-type="table" rid="tbl6">6</xref>). The bowel volume was greater in females than males with an average volume of 617.8 and 421.2&#x000a0;cm<sup>3</sup> respectively. However, achieved volumes were less than the specified OAR planning objective.</p><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><p>OAR dose/volumes achieved according to grouping</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">OAR</th><th align="left" rowspan="2" colspan="1">Constraint dose level (Gy)</th><th align="left" colspan="2" rowspan="1">Median achieved volume/dose (range) (cm<sup>3</sup>/%)</th><th align="left" rowspan="2" colspan="1"><italic>P</italic>-value</th><th align="left" colspan="2" rowspan="1">Median achieved volume/dose (range) (cm<sup>3</sup>/%)</th><th align="left" rowspan="2" colspan="1"><italic>P</italic>-value</th></tr><tr><th align="left" rowspan="1" colspan="1">Male</th><th align="left" rowspan="1" colspan="1">Female</th><th align="left" rowspan="1" colspan="1"><italic>N</italic>0&#x02013;2</th><th align="left" rowspan="1" colspan="1"><italic>N</italic>3</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Bowel (cm<sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">188.4</td><td align="left" rowspan="1" colspan="1">318.7</td><td align="left" rowspan="1" colspan="1">0.04<xref ref-type="table-fn" rid="tf6-2">*</xref></td><td align="left" rowspan="1" colspan="1">216.0</td><td align="left" rowspan="1" colspan="1">440.6</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(280.5)</td><td align="left" rowspan="1" colspan="1">(974.7)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(599.7)</td><td align="left" rowspan="1" colspan="1">(872.1)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">V45</td><td align="left" rowspan="1" colspan="1">36.3</td><td align="left" rowspan="1" colspan="1">132.3</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">59.9</td><td align="left" rowspan="1" colspan="1">152.4</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(317.3)</td><td align="left" rowspan="1" colspan="1">(916.2)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(452.1)</td><td align="left" rowspan="1" colspan="1">(884.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">20.6</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">33.8</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(286.5)</td><td align="left" rowspan="1" colspan="1">(865.7)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(424.1)</td><td align="left" rowspan="1" colspan="1">(865.7)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Bone marrow</td><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">44.6</td><td align="left" rowspan="1" colspan="1">47.3</td><td align="left" rowspan="1" colspan="1">0.05<xref ref-type="table-fn" rid="tf6-2">*</xref></td><td align="left" rowspan="1" colspan="1">45.7</td><td align="left" rowspan="1" colspan="1">54.6</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">(%)</td><td align="left" rowspan="1" colspan="1">(22.7)</td><td align="left" rowspan="1" colspan="1">(34.8)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(33.3)</td><td align="left" rowspan="1" colspan="1">(40.5)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">20.9</td><td align="left" rowspan="1" colspan="1">25.2</td><td align="left" rowspan="1" colspan="1">0.05<xref ref-type="table-fn" rid="tf6-2">*</xref></td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">32.0</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(19.6)</td><td align="left" rowspan="1" colspan="1">(33.9)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(25.9)</td><td align="left" rowspan="1" colspan="1">(36.9)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V50</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">3.8</td><td align="left" rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="tf6-2">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(0.1)</td><td align="left" rowspan="1" colspan="1">(8.9)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(1.2)</td><td align="left" rowspan="1" colspan="1">(8.9)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">External genitalia/perineum (%)</td><td align="left" rowspan="1" colspan="1">V20</td><td align="left" rowspan="1" colspan="1">61.5</td><td align="left" rowspan="1" colspan="1">74.3</td><td align="left" rowspan="1" colspan="1">0.20</td><td align="left" rowspan="1" colspan="1">61.5</td><td align="left" rowspan="1" colspan="1">80.8</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(32.7)</td><td align="left" rowspan="1" colspan="1">(56.8)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(56.8)</td><td align="left" rowspan="1" colspan="1">(31.4)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">V30</td><td align="left" rowspan="1" colspan="1">33.7</td><td align="left" rowspan="1" colspan="1">29.6</td><td align="left" rowspan="1" colspan="1">0.36</td><td align="left" rowspan="1" colspan="1">30.7</td><td align="left" rowspan="1" colspan="1">47.1</td><td align="left" rowspan="1" colspan="1">0.03<xref ref-type="table-fn" rid="tf6-2">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(39.0)</td><td align="left" rowspan="1" colspan="1">(81.0)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(80.1)</td><td align="left" rowspan="1" colspan="1">(58.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">V40</td><td align="left" rowspan="1" colspan="1">4.9</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">0.80</td><td align="left" rowspan="1" colspan="1">4.3</td><td align="left" rowspan="1" colspan="1">29.8</td><td align="left" rowspan="1" colspan="1">0.01<xref ref-type="table-fn" rid="tf6-2">*</xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(47.5)</td><td align="left" rowspan="1" colspan="1">(43.1)</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(47.5)</td><td align="left" rowspan="1" colspan="1">(27.8)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tf6-1"><p>OAR, organs at risk; Vx, volume of organ receiving xGy.</p></fn><fn id="tf6-2"><label>*</label><p>Denotes statistical significance.</p></fn></table-wrap-foot></table-wrap><p>As a function of <italic>N</italic> stage, a statistically significant difference in the achievability of V50 (<italic>P</italic>&#x000a0;=&#x000a0;0.05) for BM was found. <italic>N</italic> stage was further divided into 2 groups: <italic>N</italic>0&#x02013;<italic>N</italic>2 patients and <italic>N</italic>3 patients. Based on this grouping, the median planned volumes for all dose planning objectives were higher in those with <italic>N</italic>3 disease for the bowel and external genitalia and for the BM V30 dose level (Table<xref ref-type="table" rid="tbl6">6</xref>). This reached statistical significance for BM V50 (<italic>P</italic>&#x000a0;=&#x000a0;0.03) and external genitalia V30 (<italic>P</italic>&#x000a0;=&#x000a0;0.03) and V40 (<italic>P</italic>&#x000a0;=&#x000a0;0.01). The mean bowel and BM volumes for the <italic>N</italic>3 group were 783.8 and 559.3&#x000a0;cm<sup>3</sup> respectively. Comparatively, the mean bowel and BM volumes for <italic>N</italic>0&#x02013;<italic>N</italic>2 patients were 486.4 and 466.1&#x000a0;cm<sup>3</sup> respectively.</p><p>When these factors were tested in the logistic regression model, gender was found to be the only factor of statistical significance in the likelihood of achieving the bowel V50 constraint (<italic>P</italic>&#x000a0;=&#x000a0;0.03) and the BM V30 constraint (<italic>P</italic>&#x000a0;=&#x000a0;0.04). Logistic regression demonstrated that the model based on gender correctly classified 70% and 76.7% of data sets to achieve the V50 bowel and V30 BM planning objectives respectively.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Published data on the use of IMRT in ACC are limited in comparison to other treatment areas such as head and neck and prostate cancer. North American studies, such as the RTOG 05-29 trial, have demonstrated that ACC IMRT provides acceptable tumour control and toxicity.<xref rid="b17" ref-type="bibr">17</xref> Dosimetric studies have reported that dose to surrounding OAR, such as bowel, BM, external genitalia, bladder and femoral heads can all be significantly reduced with IMRT, whilst still delivering the prescribed dose to the tumour.<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b22" ref-type="bibr">22</xref> However, setting the priorities for each of these OAR planning objectives in IMRT is challenging in ACC due to the number of OAR.<xref rid="b15" ref-type="bibr">15</xref> The greatest challenge in ACC IMRT is the limited published evidence of specific toxicity data and has led to planning objectives that are not entirely evidence based or which are adapted from other cancer sites.</p><p>This study showed that planning objectives set for the&#x000a0;femoral heads and BM were achieved for all dose levels. In contrast, median planned dose/volume was significantly exceeded for: the V45 and V50 for the bowel (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 and 0.001), external genitalia V20 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and bladder V35 and V40 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 and <italic>P</italic>&#x000a0;=&#x000a0;0.01). This was further supported by 73% of plans failing to meet the V45 bowel objective, 80% of plans failing to meet the external genitalia V20 and 73.3% and 60% of plans failing to meet the bladder V35 and V40 objectives respectively (Table<xref ref-type="table" rid="tbl5">5</xref>). These results are similar to those reported in a study by Devisetty et&#x000a0;al. comparing IMRT to helical tomotherapy in ACC.<xref rid="b16" ref-type="bibr">16</xref> Using OAR dose planning objectives also based on the RTOG 05-29 trial, they found that the bowel V30 and V50 and bladder V30, V40 and V50 constraints could not be achieved.<xref rid="b16" ref-type="bibr">16</xref> In contrast to the present study, they found that all planning objectives set for the external genitalia could be achieved.<xref rid="b16" ref-type="bibr">16</xref> In the present study, 80% and 50% of plans failed to achieve the V20 and V30 planning objectives respectively (Table<xref ref-type="table" rid="tbl5">5</xref>). One reason for this difference is our study included the perineum with the external genitalia contour, with more of the perineum receiving dose when the inguinal nodes are treated. None of the plans compromised target volume coverage at the expense of external genitalia dose.</p><p>There could be numerous reasons why certain OAR dose planning objectives could not be achieved. In the ANROTAT project, the protocol stated that the primary objective of the plan was to achieve the required target volume coverage followed by the OAR listed in order of priority. Major and minor deviations were only specified for the bowel and femoral heads, with the other planning objectives provided as a guide to minimise dose to other OAR. Consequently, it is possible that some objectives were relaxed in order to meet those deemed a higher priority with major deviation thresholds specified. Bowel and femoral heads were given high priority as bowel toxicity should be reduced to minimise treatment breaks, and late femoral fractures have been reported following ACC radiotherapy. Another reason could be attributable to the range of experience amongst the participating centres in the use of IMRT, and specifically ACC IMRT with some centres indicating that they had not planned or planned very few IMRT ACC patients previous to this study. This was in part demonstrated by the great range of planning times that were recorded by the participating centres. Joseph and colleagues commented that the quality of the plan produced could be highly user dependent and can depend on both the experience of the planner and the time and effort expended by the planner in the optimisation process.<xref rid="b23" ref-type="bibr">23</xref></p><p>This study sought to ascertain patient and tumour factors that could influence the likelihood of achieving these constraints. The strongest relationship found was that between gender and the ability to meet the bowel and BM dose planning objectives. It was found that the median planned volumes exceeded the V45 and V50 bowel dose planning objectives in female patients. This finding is not surprising due to the differences in pelvic anatomy between men and women.<xref rid="b23" ref-type="bibr">23</xref> In this study, women had a larger bowel volume within the pelvis and therefore, more dose delivered. Bivariate analysis also demonstrated a link between <italic>N</italic> stage and the volume of irradiated BM. When dividing <italic>N</italic> stage into <italic>N</italic>0&#x02013;<italic>N</italic>2 versus <italic>N</italic>3 stage disease, significant relationships were found with external genitalia V30 and V40 also. The median volume exceeded the planning objective for all dose levels for bowel and external genitalia for those in the <italic>N</italic>3 group. <italic>N</italic>3 disease&#x000a0;represents a more advanced stage of ACC, which includes either bilateral inguinal or bilateral internal iliac nodes. Delivering &#x02018;boost&#x02019; doses to involved&#x000a0;lymph nodes will result in higher doses delivered to the bowel, BM and the perineum and external genitalia.</p><p>There are many important points that can be taken from this study. Firstly, in order to establish realistic OAR planning objectives for use in ACC IMRT, consistent contouring is imperative. The purpose of the ACC contouring guidelines published by the AGITG was to facilitate consistency in practice.<xref rid="b14" ref-type="bibr">14</xref> The establishment of OAR planning objectives in ACC IMRT, however, can be problematic as target volumes vary between patients, disease stages, variation in bowel and external genitalia/perineum volumes can be significant based on a patient's gender and body habitus. However, if target and OAR volumes are contoured in accordance with the AGITG guidelines, the following recommendations can be made based on the results of the current study: OAR planning objectives for the femoral head, BM and the bowel V30 are realistic for use in daily practice. It is important to note that the femoral head and bowel V30 dose constraints were based on published clinical evidence of dose&#x02013;toxicity correlation.<xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b18" ref-type="bibr">18</xref> It was found that the remaining planning objectives for the bowel, external genitalia and bladder were not able to be consistently achieved with the treatment planning systems available for the study, and as such, may need to be relaxed, or potentially omitted in the case of lower priority OARs (refer to Table<xref ref-type="table" rid="tbl3">3</xref>).</p><p>From our data, the irradiation of higher volumes of bowel and BM to higher doses in patients with <italic>N</italic>3 disease and in females should be expected. Positioning the patient prone on a &#x02018;belly board&#x02019; for example, may reduce the volume of bowel irradiated, particularly for female patients with higher stage nodal disease or ensuring good bladder filling to displace bowel superiorly out of the irradiated field. Strict bladder planning objectives may not be relevant when planning ACC IMRT, as DVH toxicity data correlation is not well established for the bladder.<xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b24" ref-type="bibr">24</xref> The lower planning objectives for the external genitalia, if including the perineum, (i.e., V20) may be removed. Realistic planning objectives or better understanding of what is achievable in terms of OAR doses, has the potential to minimise planning time (the mean planning time in this study was 5.7&#x000a0;h) as radiation therapists will not spend excess time attempting to achieve goals that are unable to be met. Ultimately, the development of appropriate dose constraints for OAR in ACC IMRT can only be properly generated from dose&#x02013;toxicity correlations, which is currently lacking, particularly in terms of acute toxicity outcomes, in ACC. Our study has generated hypotheses for testing in future, larger studies and data that centres are able to review and compare their own planning data with.</p><p>A major limitation of the study was that it was not specifically designed for the purpose of assessing the feasibility of dose planning objectives in IMRT for ACC but involved analysing data collected as part of the ANROTAT project. Consequently, inter-centre variation was not able to be adequately assessed as there was not one common data set planned by all centres. Another limitation is the small sample size included in this study, although being a representative mix, means that cautious interpretation of the results should be undertaken as it may have impacted on the power of the analysis to detect significant differences. It should also be noted that there were differences in the way OAR volumes were contoured between the RTOG study (on which the OAR dose planning objectives were based) and the current study. Further prospective investigation involving larger sample sizes and correlation with toxicity data is warranted and the establishment of a patient registry would be beneficial.<xref rid="b25" ref-type="bibr">25</xref></p></sec><sec><title>Conclusion</title><p>The dose planning objectives for the femoral heads, BM and bowel V30, used in the ANROTAT project, provide a good starting point for ACC IMRT planning. Achievability of other dose planning objectives for the bowel and constraints for external genitalia and bladder can be more heavily influenced by factors such as sex and <italic>N</italic> stage. To facilitate the successful use of OAR dose planning objectives, it is important to prioritise the objectives and recognise factors that affect their achievability. As centres gain more experience in IMRT planning for ACC and more specific toxicity data become available, these dose planning objectives should be reviewed and further refined.</p></sec></body><back><ack><p>The authors acknowledge to assistance and support of the following people: ANROTAT Executive Advisory Group, the ten participating centres in the ACC component of the ANROTAT project and Elizabeth Burmeister. The Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Project was funded by the Australian Government.</p></ack><sec><title>Conflict of Interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>T</given-names></name><name><surname>Kopek</surname><given-names>N</given-names></name><name><surname>Ducruet</surname><given-names>T</given-names></name><etal/></person-group><article-title>Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2007</year><volume>67</volume><fpage>1394</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">17276620</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachnic</surname><given-names>LA</given-names></name><name><surname>Winter</surname><given-names>K</given-names></name><name><surname>Myerson</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2013</year><volume>86</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">23154075</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vuong</surname><given-names>T</given-names></name><name><surname>Devic</surname><given-names>S</given-names></name><name><surname>Belliveau</surname><given-names>P</given-names></name><name><surname>Muanza</surname><given-names>T</given-names></name><name><surname>Hegyi</surname><given-names>G</given-names></name></person-group><article-title>Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>56</volume><fpage>823</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">12788191</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>P</given-names></name><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Parker</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Long-term quality of life after radiotherapy for the treatment of anal cancer</article-title><source>Cancer</source><year>2010</year><volume>116</volume><fpage>822</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20041481</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allal</surname><given-names>AS</given-names></name><name><surname>Sprangers</surname><given-names>MAG</given-names></name><name><surname>Laurencet</surname><given-names>F</given-names></name><name><surname>Reymond</surname><given-names>MA</given-names></name><name><surname>Kurtz</surname><given-names>JM</given-names></name></person-group><article-title>Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy</article-title><source>Br J Cancer</source><year>1999</year><volume>80</volume><fpage>1588</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">10408404</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glynne-Jones</surname><given-names>R</given-names></name><name><surname>Lim</surname><given-names>F</given-names></name></person-group><article-title>Anal cancer: an examination of radiotherapy strategies</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>79</volume><fpage>1290</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">21414513</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deniaud-Alexandre</surname><given-names>E</given-names></name><name><surname>Touboul</surname><given-names>E</given-names></name><name><surname>Tiret</surname><given-names>E</given-names></name><etal/></person-group><article-title>Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>56</volume><fpage>1259</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12873670</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantinou</surname><given-names>EC</given-names></name><name><surname>Daly</surname><given-names>W</given-names></name><name><surname>Fung</surname><given-names>CY</given-names></name><name><surname>Willett</surname><given-names>CG</given-names></name><name><surname>Kaufman</surname><given-names>DS</given-names></name><name><surname>Delaney</surname><given-names>TF</given-names></name></person-group><article-title>Time-dose considerations in the treatment of anal cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>1997</year><volume>39</volume><fpage>651</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9336145</pub-id></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>DC</given-names></name><name><surname>Kurtz</surname><given-names>JM</given-names></name><name><surname>Allal</surname><given-names>AS</given-names></name></person-group><article-title>The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2001</year><volume>50</volume><fpage>675</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">11395235</pub-id></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>PT</given-names></name><etal/></person-group><article-title>Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><fpage>274</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">16111597</pub-id></element-citation></ref><ref id="b11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>JK</given-names></name><name><surname>Mell</surname><given-names>LK</given-names></name><name><surname>Schomas</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience</article-title><source>J&#x000a0;Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4581</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17925552</pub-id></element-citation></ref><ref id="b12"><element-citation publication-type="other"><collab>TROG</collab><year>2012</year><comment>Newcastle TROG The assessment of new radiation oncology technologies and treatments (ANROTAT): Study protocol B (IMRT Anal Canal) Final Report, August</comment></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duchesne</surname><given-names>GM</given-names></name><name><surname>Grand</surname><given-names>M</given-names></name><name><surname>Kron</surname><given-names>T</given-names></name><etal/></person-group><article-title>Trans Tasman Radiation Oncology Group: Development of the Assessment of New Radiation Oncology Technology and Treatments (ANROTAT) Framework</article-title><source>J Med Imaging Radiat Oncol</source><year>2014</year><comment>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/1754-9485.12255">10.1111/1754-9485.12255</ext-link></comment></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>M</given-names></name><name><surname>Leong</surname><given-names>T</given-names></name><name><surname>Chander</surname><given-names>S</given-names></name><etal/></person-group><article-title>Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>83</volume><fpage>1455</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">22401917</pub-id></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menkarios</surname><given-names>C</given-names></name><name><surname>Azria</surname><given-names>D</given-names></name><name><surname>Laliberte</surname><given-names>B</given-names></name><etal/></person-group><article-title>Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans</article-title><source>Radiat Oncol</source><year>2007</year><volume>2</volume><fpage>41</fpage><pub-id pub-id-type="pmid">18005443</pub-id></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devisetty</surname><given-names>K</given-names></name><name><surname>Mell</surname><given-names>LK</given-names></name><name><surname>Salama</surname><given-names>JK</given-names></name><etal/></person-group><article-title>A multi-institutional acute gastrointestinal toxicity analysis of&#x000a0;anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy</article-title><source>Radiother Oncol</source><year>2009</year><volume>93</volume><fpage>298</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">19717198</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachnic</surname><given-names>L</given-names></name><name><surname>Winter</surname><given-names>K</given-names></name><name><surname>Myerson</surname><given-names>R</given-names></name><etal/></person-group><article-title>RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2009</year><volume>75</volume><issue>Suppl. 3</issue><fpage>S5</fpage></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myerson</surname><given-names>RJ</given-names></name><name><surname>Outlaw</surname><given-names>ED</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2009</year><volume>75</volume><fpage>428</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">19251377</pub-id></element-citation></ref><ref id="b19"><element-citation publication-type="other"><collab>NEMA</collab><year>2001</year><comment>Washington, DC Office of Publications Digital imaging and communications in medicine (DICOM) Standard</comment></element-citation></ref><ref id="b20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>WB</given-names></name><name><surname>Bosch</surname><given-names>WR</given-names></name><name><surname>Purdy</surname><given-names>JA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Leavitt</surname><given-names>DD</given-names></name><name><surname>Starkschall</surname><given-names>G</given-names></name></person-group><article-title>An interim digital data exchange standard for multi-institutional 3D conformal radiation therapy trials</article-title><source>XII International Conference on the Use of Computers in Radiation Therapy</source><year>1997</year><publisher-loc>Salt Lake City, UT</publisher-loc><publisher-name>Medical Physics Publishing</publisher-name><fpage>465</fpage><lpage>8</lpage></element-citation></ref><ref id="b21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>MA</given-names></name><name><surname>Haworth</surname><given-names>A</given-names></name><name><surname>Kearvell</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparison of DVH data from multiple radiotherapy treatment planning systems</article-title><source>Phys Med Biol</source><year>2010</year><volume>55</volume><fpage>N337</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">20463378</pub-id></element-citation></ref><ref id="b22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milano</surname><given-names>MT</given-names></name><name><surname>Jani</surname><given-names>AB</given-names></name><name><surname>Farrey</surname><given-names>KJ</given-names></name><name><surname>Rash</surname><given-names>C</given-names></name><name><surname>Heimann</surname><given-names>R</given-names></name><name><surname>Chmura</surname><given-names>SJ</given-names></name></person-group><article-title>Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><fpage>354</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16168830</pub-id></element-citation></ref><ref id="b23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>KJ</given-names></name><name><surname>Syme</surname><given-names>A</given-names></name><name><surname>Small</surname><given-names>C</given-names></name><etal/></person-group><article-title>A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancer</article-title><source>Radiother Oncol</source><year>2010</year><volume>94</volume><fpage>60</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19896229</pub-id></element-citation></ref><ref id="b24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>AN</given-names></name><name><surname>Yorke</surname><given-names>ED</given-names></name><name><surname>Marks</surname><given-names>LB</given-names></name><name><surname>Eifel</surname><given-names>PJ</given-names></name><name><surname>Shipley</surname><given-names>WU</given-names></name></person-group><article-title>Radiation dose-volume effects of the urinary bladder</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2010</year><volume>76</volume><issue>Suppl. 3</issue><fpage>S116</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20171505</pub-id></element-citation></ref><ref id="b25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palta</surname><given-names>JR</given-names></name><name><surname>Efstathiou</surname><given-names>JA</given-names></name><name><surname>Bekelman</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Developing a national radiation oncology registry: from acorns to oaks</article-title><source>Pract Radiat Oncol</source><year>2012</year><volume>2</volume><fpage>10</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24674031</pub-id></element-citation></ref></ref-list></back></article>